Dark

Check out our Level2View

DRUG
Bright Minds Biosciences Inc. Common Stock
stock NASDAQ

At Close

Apr 2, 2026 3:59:58 PM EDT

71.47USD-0.349%(-0.25)188,468

0.00Bid 0.00Ask 0.00Spread

Pre-market

0.00USD-100.000%(-71.72)0

After-hours

Apr 1, 2026 4:14:30 PM EDT

71.72USD+0.441%(+0.32)0

OverviewHistoricalExchangesShortsNews

Jan 4, 2022

04:05PM EST Bright Minds Biosciences to Present at the H.C. Wainwright GlobeNewswire Inc

Dec 6, 2021

06:50AM EST Bright Minds Biosciences (Bright Minds, BMB or the Company) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference as follows: GlobeNewswire Inc

Nov 30, 2021

04:44PM EST Bright Minds Biosciences Provides Scientific Update On Its Novel 5-HT2A Psychedelic Program For The Treatment Of Mental Diseases Benzinga

07:30AM EST Hundreds of de novo patentable psychedelic-based compounds created through discovery program GlobeNewswire Inc

Nov 15, 2021

11:09AM EST Bright Minds Biosciences Earlier Commenced Trading On Nasdaq Under Ticker 'DRUG' Benzinga

Share